Mark R. Chance, Ph.D.

Faculty Appointments

School of Medicine Vice Dean for Research

Center for Proteomics and Bioinformatics:
Director

Charles W. and Iona A. Mathias Professor of Cancer Research

Department of General Medical Sciences:
Professor (Primary)

Department of Genetics and Genome Science:
Professor (Secondary)

Academic History

1986Ph.D., Biophysics, University of Pennsylvania
1986-1988Post-doctoral Fellow, Biophysics, AT&T Bell Labs

Positions and Employment

1984-1998Visiting Scientist, AT&T Bell Laboratories, Murray Hill, NJ
1988-1992Assistant Professor in Chemistry, Georgetown University
1993-1995Director, Biostructures PRT, Beamline X9B, National Synchrotron Light Source
1994-2005Director, Molecular Biophysics Training Program, Albert Einstein College of Medicine
1995-Director, Center for Synchrotron Biosciences, National Synchrotron Light Source, Brookhaven Labs
2005-Director, Case Center for Proteomics and Bioinformatics and Cleveland Foundation Center for Proteomic Medicine
2005-2010Professor of Physiology & Biophysics, Case Western Reserve Medical School, Cleveland, OH
2006-2009CEO, NEO Proteomics, Inc. Cleveland, OH
2009-Chief Scientific Officer, NEO Proteomics, Inc. Cleveland, OH
2010-2012Professor and Interim Chair, CWRU Department of Genetics, Cleveland, OH
2010-Professor, Department of General Medical Sciences, CWRU, Cleveland, OH
2010-Professor, Department of Genetics and Genome Sciences, CWRU, Cleveland, OH
2011-Charles W. and Iona A. Mathias Professor of Cancer Research, CWRU, Cleveland, OH
2011-Vice Dean for Research, CWRU, School of Medicine, Cleveland, OH

Honors

1980Hawk Prize in Biochemistry, Wesleyan University
1980-1984NIH Graduate Fellow, Massachusetts Institute of Technology, Department of Biology
1985-1986Cardiovascular Fellow, University of Pennsylvania, Department of Biochemistry and Biophysics
1990-1992The Upjohn Company New Faculty Research Award
1995-2002Joseph & Anne Wunsch Fellow in Biophysical Engineering, Albert Einstein College of Medicine
1996-2001Irma T. Hirschl Career Scientist Award
2003Dean's Achievement Award, Albert Einstein College of Medicine
2011Charles W. and Iona A. Mathias Chair in Cancer Research

Research Interests

The research in my laboratory is focused in the important areas of structural and cellular proteomics. High throughput methods are revolutionizing structural biology through structural genomics initiatives. We are using these advances to identify the structure and function of large macromolecular complexes in areas relevant to iron transport, mis-match repair, and actin filament assembly. New technologies in mass spectrometry are also allowing protein expression, localization, and interactions to be studied in increasing detail and on a genome wide scale. Our expertise in quantitative mass spectrometry and 2-D gel technologies are being applied to identify biomarkers and regulatory pathways in colon cancer, diabetes, radiation exposure, and HIV infection.

In structural biology, structural genomics has as its goal the provision of structural models for all possible open reading frame sequences. This will be accomplished by solving the structures of 5,000-10,000 carefully selected target proteins, each one a member of a distinct protein family. The remainder of the structures will be solved by comparative modeling. Our experience in the New York Structural GenomiX Research Consortium with the 200 structures that have been solved so far is that we can model over 500 additional open reading frame sequences for each solved structure.

Although structural genomics is rapidly progressing, our progress to date clearly identifies the next biological hurdle. High-throughput structural biology is optimized to examine the structure of small soluble protein domains, while critical functions of biology are controlled by larger multi-protein complexes. The availability of high resolution domain structures is critical to understanding the assemblies, the domains must "dock" with each other in a functionally relevant fashion. The long term structural goals of my laboratory are focused on understanding the structure and dynamics of these assemblies. We are using biochemical approaches, mass spectrometry, crystallography, cryo-EM, cross-linking, footprinting, and molecular modeling to understand the physiologically relevant functional states.

In our expression proteomics studies, examining the post-translational modifications, amounts, and interactions of proteins are combined in integrated studies to understand the pathology of human disease. Working with investigators across the Case campus and across NE Ohio, we are developing new biomarkers to direct therapeutic approaches for patients, probing fundamental regulatory mechanisms of disease, and comparing these markers and regulatory mechanisms to those seen in normal development and normal physiology.